Interim results from the COMET-ICE trial showing lower mortality and progression with treatment. NCT04545060
GlaxoSmithKline et al., 5/26/2021, Double Blind Randomized Controlled Trial, USA, North America, preprint, 1 author.
risk of death, 66.6% lower, RR 0.33, p = 1.00, treatment 0 of 291 (0.0%), control 1 of 292 (0.3%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of disease progression, 85.0% lower, RR 0.15, p = 0.002, treatment 3 of 291 (1.0%), control 21 of 292 (7.2%), adjusted per study.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.